Creative Biolabs, a global leader in neuroscience research, is proud to introduce innovative platforms that advance discoveries in neurodegenerative disease research.
Looking Forward to a Golden Autumn
Pioneer Group, a specialist in life science infrastructure and venture building, has launched a new Accelerator Programme for early-stage life science companies targeting unmet needs in the management of chronic conditions.
Funded by the Innovate UK Biomedical Catalyst, in collaboration with the Medical Research Council, the Accelerator has been designed to support UK start-ups in the initial phases of their development.
This is a free event aiming to spark collaboration and productive discussion across researchers in biotech/pharma/academia alike. This year’s event will cover different therapeutic modalities and includes scientific presentations on antibody-drug conjugates (ADCs) and targeted protein degradation in oncology and neuroscience. We will also host a poster session and a closing panel discussion themed “Translational success in drug discovery.”
More details and how to register in the event link below!
Cambridge, UK: o2h Technology, a business vertical of the o2h Group, is delighted to announce the launch of the fourth edition of its Tech Kickstarter Competition. First launched in 2023, the initiative continues to support innovative seed and early-stage companies by helping them bring their ideas to life with end-to-end MVP, web, and mobile app development needs.
CancerTools.org, a unique non-profit cancer research tool supplier and part of Cancer Research UK, has chosen Discovery Park as the home of their first UK based laboratory, growing their team at the Sandwich Science and Tech campus.
Members of the Industry Skills Accelerator (ISA) have celebrated a successful year of strengthening the UK’s medicines manufacturing workforce.
LONDON, UK, and BOSTON, MA, September 2, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for AstriVax Therapeutics NV and is pleased to announce the placement of Dieter Weinand as Chair of its Board of Directors.